Trends in predominant causes of death in individuals with and without diabetes in England from 2001 to 2018: an epidemiological analysis of linked primary care records

Jonathan Pearson-Stuttard, James Bennett, Yiling J Cheng, Eszter P Vamos, Amanda J Cross, Majid Ezzati, Edward W Gregg, Jonathan Pearson-Stuttard, James Bennett, Yiling J Cheng, Eszter P Vamos, Amanda J Cross, Majid Ezzati, Edward W Gregg

Abstract

Background: The prevalence of diabetes has increased in the UK and other high-income countries alongside a substantial decline in cardiovascular mortality. Yet data are scarce on how these trends have changed the causes of death in people with diabetes who have traditionally died primarily of vascular causes. We estimated how all-cause mortality and cause-specific mortality in people with diabetes have changed over time, how the composition of the mortality burden has changed, and how this composition compared with that of the non-diabetes population.

Methods: In this epidemiological analysis of primary care records, we identified 313 907 individuals with diabetes in the Clinical Practice Research Datalink, a well described primary care database, between 2001 to 2018, and linked these data to UK Office for National Statistics mortality data. We assembled serial cross sections with longitudinal follow-up to generate a mixed prevalence and incidence study population of patients with diabetes. We used discretised Poisson regression models to estimate annual death rates for deaths from all causes and 12 specific causes for men and women with diabetes. We also identified age-matched and sex matched (1:1) individuals without diabetes from the same dataset and estimated mortality rates in this group.

Findings: Between Jan 1, 2001, and Oct 31, 2018, total mortality declined by 32% in men and 31% in women with diagnosed diabetes. Death rates declined from 40·7 deaths per 1000 person-years to 27·8 deaths per 1000 person-years in men and from 42·7 deaths per 1000 person-years to 29·5 deaths per 1000 person-years in women with diagnosed diabetes. We found similar declines in individuals without diabetes, hence the gap in mortality between those with and without diabetes was maintained over the study period. Cause-specific death rates declined in ten of the 12 cause groups, with exceptions in dementia and liver disease, which increased in both populations. The large decline in vascular disease death rates led to a transition from vascular causes to cancers as the leading contributor to death rates in individuals with diagnosed diabetes and to the gap in death rates between those with and without diabetes.

Interpretation: The decline in vascular death rates has been accompanied by a diversification of causes in individuals with diagnosed diabetes and a transition from vascular diseases to cancers as the leading contributor to diabetes-related death. Clinical and preventative approaches must reflect this trend to reduce the excess mortality risk in individuals with diabetes.

Funding: Wellcome Trust.

Copyright © 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved.

Figures

Figure 1
Figure 1
Death rates by cause in those with and without diabetes in 2001 and 2018
Figure 2
Figure 2
Absolute change in cause-specific death rates from 2001 to 2018 in those with and without diabetes
Figure 3
Figure 3
Relative change in cause-specific death rate from 2001 to 2018 in people with diabetes compared with those without diabetes
Figure 4
Figure 4
Proportional contribution to mortality burden of causes of death in people with and without diabetes

References

    1. NCD Risk Factor Collaboration (NCD-RisC) Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4.4 million participants. Lancet. 2016;387:1513–1530.
    1. Singh GM, Danaei G, Farzadfar F. The age-specific quantitative effects of metabolic risk factors on cardiovascular diseases and diabetes: a pooled analysis. PLoS One. 2013;8
    1. Genuth S, Eastman R, Kahn R. Implications of the United Kingdom prospective diabetes study. Diabetes Care. 2003;26(suppl 1):S28–S32.
    1. Fox CS, Matsushita K, Woodward M. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis. Lancet. 2012;380:1662–1673.
    1. Gregg EW, Li Y, Wang J. Changes in diabetes-related complications in the United States, 1990-2010. N Engl J Med. 2014;370:1514–1523.
    1. National Institute for Health and Care Excellence NICE clinical guidelines (NG28)—type 2 diabetes in adults. Dec 2, 2015.
    1. Gregg EW, Cheng YJ, Srinivasan M. Trends in cause-specific mortality among adults with and without diagnosed diabetes in the USA: an epidemiological analysis of linked national survey and vital statistics data. Lancet. 2018;391:2430–2440.
    1. Preis SR, Pencina MJ, Hwang SJ. Trends in cardiovascular disease risk factors in individuals with and without diabetes mellitus in the Framingham Heart Study. Circulation. 2009;120:212–220.
    1. Ezzati M, Obermeyer Z, Tzoulaki I, Mayosi BM, Elliott P, Leon DA. Contributions of risk factors and medical care to cardiovascular mortality trends. Nat Rev Cardiol. 2015;12:508–530.
    1. Unal B, Critchley JA, Capewell S. Explaining the decline in coronary heart disease mortality in England and Wales between 1981 and 2000. Circulation. 2004;109:1101–1107.
    1. Harding JL, Shaw JE, Peeters A, Davidson S, Magliano DJ. Age-specific trends from 2000–2011 in all-cause and cause-specific mortality in type 1 and type 2 diabetes: a cohort study of more than one million people. Diabetes Care. 2016;39:1018–1026.
    1. Tolman KG, Fonseca V, Dalpiaz A, Tan MH. Spectrum of liver disease in type 2 diabetes and management of patients with diabetes and liver disease. Diabetes Care. 2007;30:734–743.
    1. Gottesman RF, Albert MS, Alonso A. Associations between midlife vascular risk factors and 25-year incident dementia in the atherosclerosis risk in communities (ARIC) cohort. JAMA Neurol. 2017;74:1246–1254.
    1. Tuligenga RH, Dugravot A, Tabák AG. Midlife type 2 diabetes and poor glycaemic control as risk factors for cognitive decline in early old age: a post-hoc analysis of the Whitehall II cohort study. Lancet Diabetes Endocrinol. 2014;2:228–235.
    1. Tsilidis KK, Kasimis JC, Lopez DS, Ntzani EE, Ioannidis JPA. Type 2 diabetes and cancer: umbrella review of meta-analyses of observational studies. BMJ. 2015;350:350.
    1. Herrett E, Gallagher AM, Bhaskaran K. Data resource profile: clinical practice research datalink (CPRD) Int J Epidemiol. 2015;44:827–836.
    1. Khan NF, Harrison SE, Rose PW. Validity of diagnostic coding within the General Practice Research Database: a systematic review. Br J Gen Pract. 2010;60:e128–e136.
    1. Public Health England A review of recent trends in mortality in England. 2018.
    1. Ali MK, Bullard KM, Saaddine JB, Cowie CC, Imperatore G, Gregg EW. Achievement of goals in U.S. diabetes care, 1999–2010. N Engl J Med. 2013;368:1613–1624.
    1. Ford ES, Ajani UA, Croft JB. Explaining the decrease in U.S. deaths from coronary disease, 1980–2000. N Engl J Med. 2007;356:2388–2398.
    1. Lind M, Garcia-Rodriguez LA, Booth GL. Mortality trends in patients with and without diabetes in Ontario, Canada and the UK from 1996 to 2009: a population-based study. Diabetologia. 2013;56:2601–2608.
    1. Bennett JE, Pearson-Stuttard J, Kontis V, Capewell S, Wolfe I, Ezzati M. Contributions of diseases and injuries to widening life expectancy inequalities in England from 2001 to 2016: a population-based analysis of vital registration data. Lancet Public Health. 2018;3:e586–e597.
    1. Calvert M, Shankar A, McManus RJ, Lester H, Freemantle N. Effect of the quality and outcomes framework on diabetes care in the United Kingdom: retrospective cohort study. BMJ. 2009;338
    1. Office for National Statistics Deaths registered in England and Wales. 2018.
    1. Chatterjee S, Peters SA, Woodward M. Type 2 diabetes as a risk factor for dementia in women compared with men: a pooled analysis of 2·3 million people comprising more than 100,000 cases of dementia. Diabetes Care. 2016;39:300–307.
    1. Abarca-Gómez L, Abdeen ZA, Hamid ZA. Worldwide trends in body-mass index, underweight, overweight, and obesity from 1975 to 2016: a pooled analysis of 2416 population-based measurement studies in 128·9 million children, adolescents, and adults. Lancet. 2017;390:2627–2642.
    1. Williams R, Aithal G, Alexander GJ. Unacceptable failures: the final report of the Lancet Commission into liver disease in the UK. Lancet. 2020;395:226–239.
    1. Huxley RR, Woodward M. Cigarette smoking as a risk factor for coronary heart disease in women compared with men: a systematic review and meta-analysis of prospective cohort studies. Lancet. 2011;378:1297–1305.
    1. Cukierman-Yaffe T, Gerstein HC, Colhoun HM. Effect of dulaglutide on cognitive impairment in type 2 diabetes: an exploratory analysis of the REWIND trial. Lancet Neurol. 2020;19:582–590.
    1. Pearson-Stuttard J, Ezzati M, Gregg EW. Multimorbidity-a defining challenge for health systems. Lancet Public Health. 2019;4:e599–e600.
    1. Whitty CJ. Harveian Oration 2017: Triumphs and challenges in a world shaped by medicine. Clin Med (Lond) 2017;17:537–544.
    1. de Lusignan S, Sadek N, Mulnier H, Tahir A, Russell-Jones D, Khunti K. Miscoding, misclassification and misdiagnosis of diabetes in primary care. Diabet Med. 2012;29:181–189.
    1. Gray J, Orr D, Majeed A. Use of Read codes in diabetes management in a south London primary care group: implications for establishing disease registers. BMJ. 2003;326
    1. Diabetes UK. Diabetes prevalence. 2019.
    1. NHS Digital Health survey for England 2017. Nov 27, 2019.
    1. Lascar N, Brown J, Pattison H, Barnett AH, Bailey CJ, Bellary S. Type 2 diabetes in adolescents and young adults. Lancet Diabetes Endocrinol. 2018;6:69–80.

Source: PubMed

3
Suscribir